December 7, 2021

Volume XI, Number 341


December 06, 2021

Subscribe to Latest Legal News and Analysis

FDA Issues Final Guidance on Medical Device Benefit and Risk Analysis for 510(K)S

The FDA recently released a final guidance titled “Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics.” The guidance is intended to help applicants demonstrate substantial equivalence and to provide guidance when the benefit-risk profile of a new device is different from that of the predicate device.

The guidance begins with a high-level review of the analysis of substantial equivalence, noting that it starts with the question of whether the device for which clearance is sought has the same intended use as the predicate device. If so, then the FDA considers whether the two devices have “the same technological characteristics” or whether any differences in technological characteristics raise questions of safety and effectiveness, and whether the applicant’s device is at least as safe and effective as the predicate device.

In connection with the safety and effectiveness of the applicant’s device, the FDA will weigh “any probable benefit to health from the use of the device against any probable risk of injury or illness from such use, among other relevant factors.” Benefits and risks may be identified from performance data, which can be non-clinical or clinical. A device with decreased benefits compared to the predicate may be found substantially equivalent if it also presents decreased risks; conversely, a device with increased risks compared to the predicate may be found substantially equivalent if it also offers increased benefits.

The guidance then identifies and seeks to clarify the benefit and risk factors it considers if it has determined that any different technological characteristics do not raise different questions of safety and effectiveness. The benefit factors that the FDA will consider include:

Type of benefit(s) – examples include the device’s impact on clinical management, patient health, and patient satisfaction in the target population, such as the effect on patient management and quality of life, probability of survival, improvement of patient function, prevention of loss of function, and relief from symptoms

  • Magnitude of the benefit(s)
  • Probability of the patient experiencing one or more benefit(s)
  • Duration of effect(s)

The FDA also considers several risk factors individually and in the aggregate:

  • Severity, types, number and rates of harmful events associated with the use of the device
  • Device-related serious adverse events
  • Device-related non-serious adverse events
  • Procedure-related complications
  • Probability of a harmful event
  • Probability of the patient experiencing one or more harmful event(s)
  • Duration of harmful events
  • Risk from false-positive or false-negative results for diagnostics
  • The number of different types of harmful events that can potentially result from using the device and the severity of their aggregate effect

The guidance also identifies a number of “additional factors” that FDA considers when assessing the safety and effectiveness of an applicant’s device, including the following:

  • Uncertainty – the degree of certainty of the benefits and risks of the device
  • Characterization of the disease/condition – the disease/condition, its clinical manifestation, how it affects the patients who have it, how and whether a diagnosed disease/condition is treated, and the condition’s natural history and progression
  • Innovative Technology - when a new device has technological improvements that are important for public health, the FDA may accept greater uncertainty in an assessment of benefits and risks
  • Patient tolerance for risk and perspective on benefit
  • Benefit for the healthcare professional or caregiver – the FDA recognizes that certain devices, such as surgical tools that allow different techniques or devices that positively affect ongoing patient management, may improve the way they care for the patients and consequently improve patient outcomes
  • Risk mitigation – mitigation measures may minimize the probability of a harmful event occurring and improve the benefit-risk profile
  • Postmarket data – provides a greater understanding of risks and benefits of the device itself, and the risks and benefits of similar devices

Finally, the guidance discusses a number of specific examples of application of these various factors.

As always, the FDA’s guidance documents do not establish legally enforceable responsibilities, but rather describe the FDA’s current thinking on a topic.

© 2021 BARNES & THORNBURG LLPNational Law Review, Volume VIII, Number 278

About this Author

Lynn C. Tyler FDA Compliance Attorney Barnes & Thornburg

Lynn Tyler helps innovative companies secure and preserve their market position and competitive advantage. He advises on FDA compliance, helps protect clients with patent infringement and validity opinions, helps and enforce intellectual property rights — which often must be asserted against imitators who seek to reap where they have not sown.

An accomplished advocate, Lynn litigates and represents clients involved in virtually all stages of the dispute resolution process, including pre-litigation counseling, alternative dispute resolution, formal and informal...